Skip to main content

Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · Delayed Price · USD
20.16 -1.02 (-4.82%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap465.86M
Revenue (ttm)n/a
Net Income (ttm)-10.96M
Shares Out23.11M
EPS (ttm)-0.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,504,791
Open20.87
Previous Close21.18
Day's Range19.34 - 22.16
52-Week Range11.40 - 29.43
Betan/a
Analystsn/a
Price Target24.67 (+22.4%)
Est. Earnings DateNov 16, 2021

About AVTE

Aerovate Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus is on advancing AV-101, our dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, or PAH, a devastating disease impacting approximately 70,000 people in the United States and Europe. Imatinib, marketed as Gleevec tablets, was originally developed for the treatment of multiple cancers. Oral imatinib also demon...

IndustryBiotechnology
IPO DateJun 30, 2021
CEOTimothy P. Noyes
Employees8
Stock ExchangeNASDAQ
Ticker SymbolAVTE
Full Company Profile

Financial Performance

Financial Statements

News

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

2 days ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.   (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 month ago - GlobeNewsWire

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option ...

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

2 months ago - GlobeNewsWire

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company priced 8.68 million shares at $14, the mid...

2 months ago - Benzinga

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

2 months ago - GlobeNewsWire

Aerovate Therapeutics IPO Registration Document (S-1)

Aerovate Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC